Home › Toxemia › NCT06281665
Treatment With Aspirin After Preeclampsia: TAP Trial
Who can join
Ages 18 to 55 · Women
Full eligibility criteria
Inclusion Criteria: * Postpartum individuals ≥18 years old * Preeclampsia diagnosis Exclusion Criteria: * Fetal anomaly * Multiple gestation * Pre-pregnancy hypertension * Allergy or contraindication to low-dose aspirin * Pre-pregnancy diabetes
About the study
The objective of this research project is to conduct a single-site pilot trial to assess the feasibility and effect of low-dose aspirin to augment vascular recovery in the immediate postpartum period after preeclampsia through two specific aims: 1) to pilot test the feasibility of conducting a randomized controlled trial of postpartum low dose aspirin vs. placebo, and 2) to assess the effect of postpartum aspirin on endothelial function and blood pressure. Our central hypothesis is that postpartum administration of low-dose aspirin following preeclampsia will be feasible, improve endothelial function, and lower BP at 6 months postpartum. Subjects will undergo 3 study visits involving BP measurements, blood draws, questionnaires, and/or microiontophoresis. Up to 60 adult subjects will be enrolled at Magee-Women's Hospital.
What is being tested
- Low-dose aspirin (drug)
- Placebo (drug)
Sponsor: Malamo Countouris · Participants: 60 · Started: May 29, 2024
Contact the study team
- Alisse K Hauspurg, MD · Phone: 412-641-1381
- Sila Yavan, MS · Phone: 4124174981
Official record on ClinicalTrials.gov — NCT06281665
Locations in the U.S.
| Pennsylvania | University of Pittsburgh Magee-Womens Hospital, Pittsburgh |
Conditions
- Toxemia
- Preeclampsia
- High Blood Pressure
- High Blood Pressure in Pregnancy
- Cardiovascular Disease
- Tumors and Pregnancy
- Vascular Diseases
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.